Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Apr 17, 2018 4:21pm
182 Views
Post# 27900366

RE:RE:RE:RE:RE:RE:example

RE:RE:RE:RE:RE:RE:example Now that they have a bit of spare cash (not loads but some), clearly they don't have enough for phase 3. 
I won't if a more strategic move is to expedite ATB-352 in parallel to ATB-346. 
If they can speed up the pre clinical and and Phase 1... I have no idea how long that would take, they keep saying it should be quicker then 346 as it is for acute pain and not to be taken long term. 

Imagine this, they get through pre clinical ATB-352 sometime in Q3. They do Phase 1 Q3/Q4 then by end of year they have both ATB-346 Phase 2b + ATB-352 Phase 1 with plans for 352 phase 2 in Q1 2019. 
That would surely help fetch us a good dollar.

You'd think if this current trial was what 2.6 Million, then get through pre clinical and phase 1 for 352 it should be much less then that, we should have the cash in hand for that. 

That being said, I have no clue if its technically feasible to do. Everything takes a long time. 

They need to make a deal prior to Phase 3, so the more products they have in better shape would have to increase the deal they can strike.

I'm probably dreaming here.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities